1. Home
  2. JLS vs SCLXW Comparison

JLS vs SCLXW Comparison

Compare JLS & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

HOLD

Current Price

$17.95

Market Cap

98.7M

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.14

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JLS
SCLXW
Founded
2009
N/A
Country
United States
United States
Employees
N/A
30
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.7M
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JLS
SCLXW
Price
$17.95
$0.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.0K
2.3K
Earning Date
01-01-0001
03-07-2025
Dividend Yield
9.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
$16.80
$0.04
52 Week High
$19.09
$0.64

Technical Indicators

Market Signals
Indicator
JLS
SCLXW
Relative Strength Index (RSI) 38.62 49.50
Support Level $17.48 $0.10
Resistance Level $18.89 $0.18
Average True Range (ATR) 0.38 0.02
MACD -0.02 0.00
Stochastic Oscillator 37.96 51.61

Price Performance

Historical Comparison
JLS
SCLXW

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: